Diamyd Medical
9.47 SEK
-1.56 %
Less than 1K followers
DMYD B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Investor consensus
-1.56 %
-7.34 %
-21.99 %
-2.97 %
-42.13 %
-36.74 %
-37.93 %
-68.46 %
+215.38 %
Diamyd Medical is active in diabetes research. The company has developed a vaccine that contains the active ingredient and molecule GAD, a substance that has the potential to be an important part of the prevention of diabetes treatments in the future. The company has operations on a global level with the largest presence in the Nordic region. The headquarters are located in Stockholm.
Read moreMarket cap
1.3B SEK
Turnover
1.64M SEK
Revenue
130K
EBIT %
-140,953.85 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
Revenue M
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
28.1
2026
Interim report Q1'26
25.3
2026
Interim report Q2'26
24.6
2026
Interim report Q3'26
All
Press releases
ShowingAll content types
Diamyd Medical AB: Annual Report 2024/2025
BioStock: Lif's sustainability conference 2025 with a focus on transition, competitiveness and sustainable production
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools